Relmada Corp - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים RLMD

Relmada Therapeutics (RLMD) is recognized as a promising developer of fast-acting therapies for CNS disorders. The year-over-year sales trend over a 12-month period demonstrates revenue dynamics, where the value of 0.00 characterizes this level. Patent protection allows the company to avoid price wars when implementing innovations, however, reliance on a single drug, REL-1017, and a capital deficit create serious risks.
relmada.com (RLMD) - פילוחי מדדים ודוחות פיננסיים

Relmada Therapeutics (RLMD) focuses on developing innovative CNS therapies within a stable US legal framework. The year-over-year (TTM) revenue dynamics measure the growth rates of trailing twelve-month income. This chart's continuous line smooths out reporting gaps, revealing the actual resilience of the business. The humanitarian status of medicine minimizes geopolitical risks for this metric. A stable trend confirms the quality of capital management.